Aktieinformation Abbvie | Filter  Basic-Info

Abbvie

The past year was a good year for Abbvie investors

The period between December 2015 and December 2016 was a good period for the investors. The stock gained almost 11 percent. Over the period 2011-2016 the stock lost a modest 0 percent. Abbvie's revenues between 2011 and 2015 were very volatile and moved between 18,38 billion dollars and 0 million dollars. The net results between 2011 and 2015 were far from constant and fluctuated between 3,43 billion dollars and 0 million dollars.

Abbvie's head office is located in North Chicago. Abbvie is active in the biotech sector. Mr. Richard A. Gonzalez is the company' CEO. Mr. William J. Chase is financially responsible for the company as CFO. The past 10 years the (international) industry gained at around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

Abbvie paid out dividends in the past 5 years. On average the Abbvie stock yielded a delivered a dividend yield of around 3,2 percent over the past 5 years.

At the end of 2015 around 26 thousand people were on Abbvie' payroll.

Abbvie financed with a quite low debt position

At the end of 2015 the biotech company's balance sheet equaled 0 million dollars. Of the total balance sheet 0 million dollars ( percent) was financed by debt.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 0 million dollars.

All the annual reports of Abbvie are available here. More information about Abbvie can be found it's website. .